BNGO Q3'26 Earnings: revenue estimate is 8.44M USD

What happened

Bionano Genomics is scheduled to report its Q3’26 results on November 10 after the market closes, with disclosure expected at 4:05 p.m. ET. The revenue estimate is 8.44M USD, and earnings per share are estimated at a loss.

Confirmed

Global impact / market context

The estimates set expectations for the quarter, but do not show what Bionano actually earned or whether it met them. Reported revenue and loss per share could influence investor views of demand and the company’s ability to cover costs, though the article gives no cash or spending details.

Analyst inference

The article gives a Q3’26 revenue forecast above the prior quarter’s estimate and forecasts a smaller loss per share than before. These are estimates, not reported results; if sales or losses differ, investors may reassess the company’s revenue trajectory and spending needs.

Analyst inference

What to watch

1. When results are released, compare reported revenue with the stated estimate; sales above or below expectations could change views of Bionano Genomics’ near-term revenue direction. Analyst inference
2. Check reported earnings per share, meaning profit or loss allocated to each share, against the forecast; the actual result may clarify whether costs are improving or worsening. Analyst inference
3. Look for explanations of sales and costs in the results; these details can show whether any change is driven by revenue or spending, rather than estimates alone. Analyst inference

Evidence

• Original source link unavailable